Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

High-affinity inhibitors of human NAD-dependent 15-hydroxyprostaglandin dehydrogenase: mechanisms of inhibition and structure-activity relationships.

Niesen FH, Schultz L, Jadhav A, Bhatia C, Guo K, Maloney DJ, Pilka ES, Wang M, Oppermann U, Heightman TD, Simeonov A.

PLoS One. 2010 Nov 2;5(11):e13719. doi: 10.1371/journal.pone.0013719.

2.

Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.

Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):630-5. doi: 10.1016/j.bmcl.2013.11.081. Epub 2013 Dec 4.

3.
4.

Key NAD+-binding residues in human 15-hydroxyprostaglandin dehydrogenase.

Cho H, Hamza A, Zhan CG, Tai HH.

Arch Biochem Biophys. 2005 Jan 15;433(2):447-53.

PMID:
15581601
5.

Role of glutamine 148 of human 15-hydroxyprostaglandin dehydrogenase in catalytic oxidation of prostaglandin E2.

Cho H, Huang L, Hamza A, Gao D, Zhan CG, Tai HH.

Bioorg Med Chem. 2006 Oct 1;14(19):6486-91. Epub 2006 Jul 7.

PMID:
16828555
6.
7.
9.

Potent and selective inhibitors of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (HPGD).

Jadhav A, Niesen FH, Schultz L, Oppermann U, Maloney DJ, Simeonov A.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Mar 4 [updated 2011 Mar 11].

10.
11.

Critical residues for the coenzyme specificity of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase.

Cho H, Oliveira MA, Tai HH.

Arch Biochem Biophys. 2003 Nov 15;419(2):139-46.

PMID:
14592457
12.

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.

Bullock AN, Russo S, Amos A, Pagano N, Bregman H, Debreczeni JE, Lee WH, von Delft F, Meggers E, Knapp S.

PLoS One. 2009 Oct 20;4(10):e7112. doi: 10.1371/journal.pone.0007112.

13.

NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions.

Tai HH, Cho H, Tong M, Ding Y.

Curr Pharm Des. 2006;12(8):955-62. Review.

PMID:
16533162
14.

Endogenous inhibitors of human placental prostaglandin dehydrogenase.

Mibe M, Nagai K, Oshige T, Mori N.

Prostaglandins Leukot Essent Fatty Acids. 1992 Jul;46(3):241-5.

PMID:
1508959
16.

15-Hydroxyprostaglandin dehydrogenase.

Ensor CM, Tai HH.

J Lipid Mediat Cell Signal. 1995 Oct;12(2-3):313-9. Review.

PMID:
8777575
17.

Structural basis for substrate specificity in human monomeric carbonyl reductases.

Pilka ES, Niesen FH, Lee WH, El-Hawari Y, Dunford JE, Kochan G, Wsol V, Martin HJ, Maser E, Oppermann U.

PLoS One. 2009 Oct 20;4(10):e7113. doi: 10.1371/journal.pone.0007113.

18.

15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy.

Na HK, Park JM, Lee HG, Lee HN, Myung SJ, Surh YJ.

Biochem Pharmacol. 2011 Nov 15;82(10):1352-60. doi: 10.1016/j.bcp.2011.08.005. Epub 2011 Aug 11.

PMID:
21856294
19.

Studies on 15-hydroxyprostaglandin dehydrogenase with various prostaglandin analogues.

Ohno H, Morikawa Y, Hirata F.

J Biochem. 1978 Dec;84(6):1485-94.

20.

Control of the intracellular levels of prostaglandin E₂ through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing.

Choi D, Piao YL, Wu Y, Cho H.

Bioorg Med Chem. 2013 Aug 1;21(15):4477-84. doi: 10.1016/j.bmc.2013.05.049. Epub 2013 Jun 4.

Supplemental Content

Support Center